THERAPY DOSSIER · th-24a668b6e01a

Formoterol

Drug · Long-acting beta-2 adrenergic receptor agonist (direct interaction, disease efficacy; FDA label reference), raising intracellular cAMP. Beyond bronchodilation, the beta-2/cAMP/PGC-1alpha axis drives mitochondrial biogenesis, which is the property invoked in the trauma and acute-injury literature. ATC R03AC13 and R03CC15; USAN stem -terol. The R,R-enantiomer arformoterol (CHEMBL1363) was approved separately in 2006.

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Long-acting beta-2 adrenergic receptor agonist (direct interaction, disease efficacy; FDA label reference), raising intracellular cAMP. Beyond bronchodilation, the beta-2/cAMP/PGC-1alpha axis drives mitochondrial biogenesis, which is the property invoked in the trauma and acute-injury literature. ATC R03AC13 and R03CC15; USAN stem -terol. The R,R-enantiomer arformoterol (CHEMBL1363) was approved separately in 2006.
Target: CHEMBL210 (beta-2 adrenergic receptor)
Injury models: TBI
Reported indication: Not recorded
First approval: 2001
Development stage: Not recorded
ChEMBL record: CHEMBL1256786 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Oxis; Foradil; Eformoterol; Formoterol fumarate; Formoterol fumarate dihydrate; Perforomist; BD-40A; CGP-25827A; YM-08316; Arformoterol (R,R-enantiomer, CHEMBL1363)
Note: Not recorded

Clinical trials 6

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00215436 ↗PHASE3completed

12-week placebo- and active-controlled trial of formoterol fumarate inhalation solution 20 mcg in chronic obstructive pulmonary disease

COPD

Enrolment: 345 · Results not recorded

NCT03022097 ↗PHASE3completed

24-week study of aclidinium bromide/formoterol fumarate vs individual components and placebo in stable COPD

COPD

Enrolment: 1625 · Results not recorded

NCT00383240 ↗PHASE3completed

26-week placebo-controlled study of mometasone furoate/formoterol fumarate vs monotherapy in persistent asthma

Asthma

Enrolment: 781 · Results not recorded

NCT05202262 ↗PHASE3completed

24-week study of budesonide and formoterol fumarate MDI vs budesonide MDI and Symbicort Turbuhaler in inadequately controlled asthma (VATHOS)

Asthma

Enrolment: 645 · Results not recorded

NCT00931385 ↗PHASE3completed

24-hour FEV1-time profiles of inhaled BI 1744 CL and inhaled Foradil (formoterol) in COPD

Pulmonary Disease, Chronic Obstructive

Enrolment: 99 · Results not recorded

NCT01980615 ↗PHASE1completed

Phase I single-dose crossover safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate inhalation aerosol in healthy volunteers

Healthy Volunteers

Enrolment: 84 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32289370 ↗2020Reported benefit

Formoterol, a beta-adrenoreceptor agonist, induces mitochondrial biogenesis and promotes cognitive recovery after traumatic brain injury.

MouseTBIControlled cortical impactC57BL/6MaleIntraperitoneal0.3 mg/kgFirst dose 15 min after controlled cortical impact

Model: Controlled cortical impact traumatic brain injury

Formoterol increased cortical mitochondrial DNA copy number and cortical and hippocampal respiration, raised hippocampal mitochondrial calcium buffering capacity, restored novel object recognition and Morris water maze performance, and increased hippocampal neuron numbers and white matter sparing,…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…

Formoterol